BLAINTRAVENOUSINJECTABLEPriority Review
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIBTAYO (cemiplimab-rwlc) is a monoclonal antibody immunotherapy that blocks PD-1 to enhance anti-tumor immune response. It is approved for treatment of cutaneous squamous cell carcinoma and other solid tumors. The drug works by releasing immune checkpoints to enable T-cell activation against cancer cells.
$6MPart D
PeakProduct is in peak commercial phase with 542 linked job openings, indicating substantial ongoing commercial and manufacturing infrastructure investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
Started Oct 2022
500 enrolled
Non-small Cell Lung Cancer
Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC
Started Jun 2020
3 enrolled
Cutaneous Squamous Cell CarcinomaCutaneous Squamous Cell Carcinoma of the Head and Neck
Career Relevance
LIBTAYO careers are concentrated in operations, quality, and regulatory—reflecting a peak-lifecycle biologic with established manufacturing and compliance demands. This product offers stability and specialized expertise development rather than launch-phase dynamic roles.
Worked on LIBTAYO at Regeneron? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.